NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal [Committee B] meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 22 January 2019, from 10am to 3pm

**Location:** Prospero House 241 Borough High Street London SE1 1GA

# Committee members present

1. Dr Amanda Adler [Chair] Present for all items (Chair for items 1 to 4 and 6 to 7)
2. Dr Sanjeev Patel [Vice Chair] Present for all items (Chair for item 5)
3. Professor John Cairns Present for all items
4. Mr Diar Fattah Present for all items
5. Ms Susan Faulds Present for all items
6. Mr Richard Hoddes Present for all items
7. Mr Gareth Hooper Present for all items
8. Megan John Present for all items
9. Dr Sanjay Kinra Present for all items
10. Dr Nicholas Latimer Present for all items
11. Professor Stephen Palmer Present for all items (present as an Evidence Review Group representative for item 5)
12. Professor Allyson Pollock Present for all items
13. Dr Stephen Smith Present for all items
14. Mr William Turner Present for all items
15. Professor Nicky Welton Present for all items
16. Professor Sarah Wild Present for all items
17. Dr Stuart Williams Present for all items
18. Mr Tony Wootton Present for all items

# NICE staff present:

Helen Knight, Programme Director Present for all items

Jasdeep Hayre, Associate Director Present for all items

Dr Linda Landells, Associate Director Present for all items

Nicole Elliott, Associate Director Present for all items

Jeremy Powell, Project Manager Present for all items

Sandra Aleknavice, Administrator Present for all items

Iordanis Sidiropoulos,Technical Analyst Present for items 1 to 31

Ross Dent, Technical Adviser Present for item 5

Alan Lamb, Technical Analyst Present for items 5

Adam Brooke, Technical Analyst Present for item 6

Ahmed Elsada, Technical Adviser Present for item 6

Lindsay Claxton, Research Fellow In Health Economics, Centre for Reviews and Dissemination and Centre for Health Economics, University of York Present for all items

Nigel Fleeman, Research Associate, Liverpool Reviews and Implementation Group (LRiG) Present for item 6

Tosin Lambe, Research Associate, Liverpool Reviews and Implementation Group (LRiG) Present for item 6

Angela Stainthorpe, Research Associate, Liverpool Reviews and Implementation Group (LRiG) Present for items 32 to 42

Helen Barnett, Medical Editor Present for all items

Omar Moreea, Technical Analyst Present for all items

# External group representatives present:

Ko Jung Ong, NHS England Present for all items

1. Introduction to the meeting
2. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of certolizumab pegol for treating chronic plaque psoriasis [ID1232], tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060] and nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182].
3. News and announcements
   1. None.
4. Appraisal of certolizumab pegol for treating chronic plaque psoriasis [ID1232]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from UCB
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Ms Susan Faulds, Mr Richard Hoddes, Mr Gareth Hooper, Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Professor Stephen Palmer, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Professor Sarah Wild, Dr Stuart Williams and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol for treating chronic plaque psoriasis [ID1232].
  + 1. Mr Diar Fattah declared a personal non-specific financial interest as he has received consultancy fees from Novartis in another disease area
    2. It was agreed that Mr Fattah could participate in the appraisal
    3. Mr Christopher O’Regan declared a personal specific financial interest before the meeting as he works for MSD, the manufacturer of a comparator drug
    4. It was agreed that Mr O’Regan would not participate in this appraisal
  1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy
  3. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
     1. The committee discussed confidential information submitted for this item.
  4. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.

1. Appraisal of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Almirall
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
      3. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Ms Susan Faulds, Mr Richard Hoddes, Mr Gareth Hooper, Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Professor Sarah Wild, Dr Stuart Williams and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of tildrakizumab for treating chronic plaque psoriasis after systemic therapy [ID1060].
      4. Mr Diar Fattah declared a personal non-specific financial interest as he has received consultancy fees from Novartis in another disease area.
      5. It was agreed that Mr Fattah could participate in the appraisal
      6. Mr Christopher O’Regan declared a personal specific financial interest before the meeting as he works for MSD, the manufacturer of a comparator drug
      7. It was agreed that Mr O’Regan would not participate in this appraisal
      8. The Chair/Vice Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
      9. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
      10. 26. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
   2. Part 2 - Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting].
      1. The committee then agreed on the content of theFinal Appraisal Determination [FAD]. The committee decision was reached by consensus..
      2. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.
2. Appraisal of untreated metastatic renal cell carcinoma [ID1182]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Bristol-Myers Squibb
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Ms Susan Faulds, Mr Richard Hoddes, Mr Gareth Hooper, Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Professor Stephen Palmer, Professor Allyson Pollock, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton, Professor Sarah Wild, Dr Stuart Williams and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182].
  + 1. Mr Diar Fattah declared a personal non-specific financial interest as he has received consultancy fees from Novartis in another disease area  
       - It was agreed that Mr Fattah could participate in the appraisal
    2. The Chair/ introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
    3. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
    4. 39. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
    5. The Chair then thanked company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee B) will be held on Tuesday 19 February 2019 and will start promptly at 10am